Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02174731 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,133
- Enrollment target
NCT02174731: Completed Phase 3 study, sponsored by AstraZeneca.
NCT02174731 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 2,133 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (176% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02174731, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,133 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of roxadustat compared to epoetin alfa for the treatment of anemia in chronic kidney disease patients on dialysis.
Primary Outcome
Baseline Hb was defined as the mean of the three last central laboratory Hb values from the screening and randomization visits. Mean change in Hb from baseline to the participants mean level from Week 28 to Week 52 was analyzed using a missing at random (MAR) based multiple imputation Analysis of Covariance (ANCOVA). Baseline Hb was used as a covariate and treatment group, cardiovascular (CV) history, geographic region and dialysis duration as fixed effects. The adjusted least squares (LS) mean
Interventions
- DRUG Epoetin alfa
- DRUG Roxadustat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,133 participants |
| Start Date | 2014-07-01 |
| Est. Completion | 2018-09-26 |
| Phase | Phase 3 |
What the finished NCT02174731 record still lists
NCT02174731 is an interventional study that assigns participants to a tested intervention. Its 2,133 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (176% higher).
The record links to 0 conditions, and to 2 interventions - of which Epoetin alfa is the first listed.
NCT02174731 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02174731 about?
NCT02174731 is a clinical study titled "Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.". The purpose of this study is to evaluate the efficacy and safety of roxadustat compared to epoetin alfa for the treatment of anemia in chronic kidney disease patients on dialysis.
What is the current status of trial NCT02174731?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,133 participants. The study started on 2014-07-01. Estimated completion is 2018-09-26.
What interventions are being tested in trial NCT02174731?
The interventions under investigation include: Epoetin alfa (DRUG), Roxadustat (DRUG).
Who is sponsoring clinical trial NCT02174731?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02174731's enrollment target sits among peer trials
2,133 97th of 2000 higher than 1,904 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05650658 · 2,136 participants · NA
Left vs Left Randomized Clinical Trial
- NCT07431281 · 2,130 participants · Phase 3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- NCT03488693 · 2,140 participants · Phase 3
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
- NCT06598475 · 2,142 participants · NA
Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve Provider Recommendation and HPV Vaccination Rates Among Latino/a Adolescents
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI